TL;DR
Get everyday helpers delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A small randomized trial found that people with mild to moderate multiple sclerosis who received N-acetylcysteine (NAC) had changes in brain connectivity and glucose metabolism after about four months. Participants also reported improvements in several symptoms, but the early study does not establish that NAC treats MS or confirm the clinical value of the imaging changes.
A small randomized trial found that N-acetylcysteine (NAC), given alongside standard care, was associated with changes in brain connectivity and glucose metabolism in people with mild to moderate multiple sclerosis. Participants receiving NAC also reported improvements in pain, fatigue, cognition and attention, but the study was small and does not establish the antioxidant as an effective MS treatment.
The trial randomized 36 people with MS: 18 received NAC plus standard care, and 18 received standard care alone. The NAC group received an intravenous dose of 50 milligrams per kilogram once a week, plus 500 milligrams by mouth twice daily on the other six days of each week. Participants were assessed at the start and again after about four months, with the follow-up timing allowed to vary by two months.
Researchers used an integrated PET-MRI platform, including resting blood oxygen level-dependent functional MRI and fluorodeoxyglucose PET. Compared with the control group, the NAC group showed changes in functional connectivity in the inferior frontal region, cerebellum, and parts of the temporal and parietal lobes. PET scans showed corresponding increases in glucose metabolism in several areas, including the inferior frontal and inferior temporal gyri.
Only the NAC group showed reported clinical improvements over the study period, according to the report. The changes were in self-reported scores for pain, fatigue, cognition and attention; the reported P values were 0.015, 0.016, 0.036 and 0.010, respectively. The researchers also reported that cognitive and attention improvements correlated with imaging changes. These results are associations from a small trial, not proof that the brain imaging changes caused the reported symptom improvements.
Testing NAC Beyond Inflammation
The findings offer an early look at whether a treatment aimed at oxidative stress could affect brain measures and symptoms in MS. The study’s presenter, Sahar Darabi Monadi of Thomas Jefferson University, said many approved MS treatments target inflammation, while oxidative stress is another process researchers are investigating in relation to neurodegeneration. That framing describes the study’s rationale; this trial does not show that NAC prevents neurodegeneration or changes the course of MS.
The imaging results matter because they give researchers a way to examine possible brain effects alongside reported symptoms. But an observed change in connectivity or glucose metabolism is not by itself evidence of a lasting or meaningful health benefit. Larger and longer studies would be needed to determine whether the findings can be replicated, how they relate to day-to-day functioning, and whether a particular NAC regimen is safe and useful for people with MS.
N-acetylcysteine supplement for MS
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
How the Trial Was Designed
NAC is an antioxidant that can increase levels of glutathione, a substance involved in the body’s antioxidant defenses. The research team studied it as a possible way to address oxidative stress, rather than as a replacement for standard MS care. Both trial groups continued to receive standard care, according to the report.
The researchers combined intravenous and oral NAC. Co-author Andrew Newberg said the team chose this approach partly because prior data suggested absorption of oral NAC can vary. Earlier work had investigated NAC in other neurological conditions, but those studies do not establish its effectiveness in MS. The MS findings were presented at the American Society of Functional Neuroradiology meeting and published in IBRO Neuroscience Reports, according to MedPage Today.
““The imaging findings seemed to correspond to some of the clinical improvements people were reporting.””
— Andrew Newberg, Thomas Jefferson University
Limits of the Early Findings
The trial included only 36 participants, and the follow-up was about four months, with a permitted range of two months in either direction. The report does not establish whether the imaging or symptom changes persist, whether they translate into meaningful improvements in daily life, or whether NAC affects disability or disease progression. It also does not settle which dose, route or duration would be appropriate.
The symptom results were based on participant questionnaires, and the reported link between some symptom changes and imaging does not establish cause and effect. The source material does not provide enough detail to assess all trial methods or the size of the effects. NAC should not be treated as a proven MS therapy on the basis of this study; treatment decisions should be discussed with a qualified health professional.
Further Trials Needed on Dosing
Newberg said the team hopes the initial results will lead to more detailed research to clarify NAC dosing, treatment duration and timing. Future studies would need to test the findings in larger groups and assess whether changes in imaging and self-reported symptoms are reproducible and sustained. The report does not specify a date for another trial or describe a confirmed next study.
Key Questions
What did the MS study find about NAC?
In a trial of 36 people with mild to moderate MS, the group receiving NAC plus standard care showed changes in brain connectivity and glucose metabolism. Participants in that group also reported improvements in pain, fatigue, cognition and attention.
Does this study prove NAC treats multiple sclerosis?
No. The small, relatively short study reports preliminary findings and does not show that NAC changes MS progression or provides a lasting clinical benefit.
How was NAC given in the trial?
The treatment group received 50 mg/kg intravenously once a week and 500 mg orally twice daily on the other six days of each week, in addition to standard care.
What remains unknown about NAC for MS?
Researchers still need to determine whether the results can be replicated, whether any benefits last, and what dose and treatment duration may be appropriate. The study does not establish the clinical meaning of the imaging changes.
Source: rss
Fall Picks
fall essentials
As an affiliate, we earn on qualifying purchases.
